You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生制药(01177.HK)盐酸安罗替尼胶囊获批第四个适应症
阿思达克 02-04 16:42
中生制药(01177.HK)公布,自主研发的抗肿瘤药「盐酸安罗替尼胶囊」(商品名:福可维)已获国家药品监督管理局颁发药品注册证书,批准用於治疗甲状腺髓样癌,是继晚期非小细胞肺癌、软组织肉瘤、小细胞肺癌後,安罗替尼获批的第四个适应症。

安罗替尼获批新适应症,成为国内首个可用於治疗甲状腺髓样癌的靶向药。公司表示,安罗替尼与化疗、PD-1、PD-L1的联合用药正在广泛布局,目前有20余项临床试验进入二期或三期临床,同时有针对10多个癌种的临床研究进入二期或三期临床,预期安罗替尼适应症将不断拓展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account